论文部分内容阅读
目的评价10-羟基喜树碱(拓僖,HCPT)联合异环磷酰胺(IFO)化疗方案治疗进展期铂类耐药非小细胞肺癌(NSCLC)的有效性及安全性。方法经组织和(或)细胞学证实的Ⅲb~Ⅳ期NSCLC患者,曾有≥2次标准含铂方案联合化疗史。化疗方案为HCPT6mg/m2,d1~4;IFO1.2g/m2,d1~3;每4周重复1次。结果29例患者入组,化疗后部分缓解(PR)3例、无变化(NC)20例、疾病进展(PD)6例,治疗总有效率为13.6%,疾病控制率为72.7%,中位生存期为10.3个月。中位疾病进展时间为4.2个月。化疗的毒副反应主要为白细胞计数中度下降、轻或中度胃肠道反应及皮疹。结论HCPT联合IFO作为铂类耐药的复治方案治疗进展期NSCLC有较好的疗效及安全性。
Objective To evaluate the efficacy and safety of 10-hydroxycamptothecin (TQ, HCPT) combined with ifosfamide (IFO) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Tissue and / or cytology confirmed Ⅲb ~ Ⅳ NSCLC patients, there are ≥ 2 times the standard platinum regimen combined with chemotherapy. Chemotherapy for HCPT6mg / m2, d1 ~ 4; IFO1.2g / m2, d1 ~ 3; repeat once every 4 weeks. Results Twenty-nine patients were enrolled in the study. There were 3 patients with partial remission (PR) after chemotherapy and 20 patients with no change (NC) and 6 patients with progressive disease (PD). The total effective rate was 13.6% and the disease control rate was 72.7% Survival of 10.3 months. The median progression time was 4.2 months. Toxic side effects of chemotherapy mainly for moderate decline in white blood cell count, mild or moderate gastrointestinal reactions and rash. Conclusion HCPT combined with IFO as a platinum-resistant regimen for the treatment of advanced NSCLC has good efficacy and safety.